2022
Ketones: the double-edged sword of SGLT2 inhibitors?
Lupsa BC, Kibbey RG, Inzucchi SE. Ketones: the double-edged sword of SGLT2 inhibitors? Diabetologia 2022, 66: 23-32. PMID: 36255460, DOI: 10.1007/s00125-022-05815-1.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsSGLT2 inhibitorsDrug categoriesSodium-glucose cotransporter 2 inhibitorsCardio-renal benefitsNormal blood glucose concentrationsCotransporter 2 inhibitorsClasses of medicationsAnti-inflammatory effectsSerious adverse effectsType 1 diabetesBlood glucose levelsBlood glucose concentrationKidney outcomesRare complicationBlood pressureSGLT2 inhibitionGlucose levelsKetone levelsBody weightType 2Ketone bodiesAdverse effectsGlucose concentrationInhibitorsEdged sword
2019
Personalized Management of Type 2 Diabetes
Peter PR, Lupsa BC. Personalized Management of Type 2 Diabetes. Current Diabetes Reports 2019, 19: 115. PMID: 31686226, DOI: 10.1007/s11892-019-1244-0.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsType 2 diabetesManagement of patientsUnique patient characteristicsSpecific patient subpopulationsClass of agentsGlycemic targetsTreatment landscapeMedical therapyPatient characteristicsPharmacotherapeutic optionsPatient subpopulationsIndividualized carePersonalized managementClinical practiceType 2ReviewOur goalRecent FindingsWePatientsDiabetesTherapyManagementPhysiciansCare